
Aakash Desai/LinkedIn
Feb 12, 2025, 08:59
Aakash Desai: LUPER – Lurbinectedin plus pembrolizumab in SCLC
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared an article Antonio Calles and colleagues authored post on X:
“In JTO online, LUPER: lurbinectedin + pembrolizumab in SCLC
• RR: 46.4% (3 CR)
• DOR: 7.8m | PFS: 4.6m | OS: 10.5m
My Takeaway? Limited impact—IO is standard in 1L, and emerging 2L options post-IO show strong efficacy as well.”
Authors: Antonio Calles et al.
Aakash Desai
Alejandro Navarro
Antonio Calles
Bernard Gaston Doger Speville Uribe
cancer
Daniel Alcalá-López
Elena Corral de la Fuente
Emiliano Calvo
Enric Álvarez Colomé
Enriqueta Felip
Ernest Nadal
Jorge Ramon-Patino
Jose Rodríguez-Morató
Maria de Miguel
Maria Jove
Marta Arregui
Melissa Fernández-Pinto
Olga Boix
OncoDaily
Oncology
Pedro Rocha
Ramón Palmero
Rosa Álvarez
Victor Moreno
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 13, 2025, 14:26
Mar 13, 2025, 10:43
Mar 13, 2025, 10:14
Mar 13, 2025, 10:06
Mar 13, 2025, 09:32
Mar 13, 2025, 09:10
Mar 13, 2025, 09:07
Mar 13, 2025, 08:55
Mar 13, 2025, 08:44